The sun has been shining on the biopharmaceutical sector of late as investors have returned to the sector big time. As a result, the BioWorld Biopharmaceutical index grew a healthy 6.6 percent in the second quarter, well ahead of the general markets, thanks to a late June spurt in valuations, causing the index to grow 5.8 percent last month. In contrast, the Nasdaq Composite index lost almost 1 percent in value in June and closed the quarter up 3.9 percent, and the Dow Jones Industrial Average eked out a 1.6 percent jump in value for the month and was up 3.3 percent for the quarter.
Trovagene Inc., of San Diego, said it engaged CRO PRA Health Sciences to conduct its phase Ib/II trial of PCM-075, a polo-like kinase 1 inhibitor, in patients with acute myeloid leukemia.
Decibel Therapeutics Inc., of Boston, said it received an undisclosed equity investment from GV, formerly Google Ventures, in which GV will also contribute its technical expertise to Decibel.
Health Canada implemented new regulations to allow the limited import of specific drugs urgently needed in the country that have yet to be authorized by the agency.
The widespread Ebola outbreak in West Africa in 2013 to 2016 drew worldwide attention and assistance to the continent and calls for local and global collaboration to target neglected tropical diseases.
HONG KONG – Facing increased U.S. regulatory scrutiny, India's largest drugmaker, Sun Pharmaceutical Industries Ltd., is outsourcing some of its manufacturing in a deal that provides South Korea's Samsung Biologics Co. Ltd., the biologics manufacturing arm of the Samsung conglomerate, an opportunity to expand its market share.
LONDON – Angle plc has delivered positive results for its live whole cell liquid biopsy in the diagnosis of ovarian cancer and said the technology is now ready for application as the basis of companion diagnostics for use with targeted cancer therapies.
RSS